SCHEMBL4095460

SCHEMBL4095460

CC(C)(C)c1ccc2c(N3CCCC3)nc(Nc3cccc(Cl)c3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 2/20 0.47
GBA1 P04062 1/20 0.46
LMNA P02545 5/20 0.45
MAPT P10636 4/20 0.45
HTT P42858 4/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 2/20 0.45
RECQL P46063 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TAAR1 Q96RJ0 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX12 P18054 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084773 0.88 LMNA (0.58) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL4090388 0.85 LMNA (0.47) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL4100471 0.77 HRH4 (0.56) KMT2AMEN1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4092170 0.75 HRH4 (0.45) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL4095286 0.72 MAPT (0.54) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL4085159 0.72 KMT2A (0.49) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL26458877 0.70 LMNA (0.80) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL5404396 0.66 MEN1 (0.54) KMT2AMEN1HRH4
SCHEMBL28374989 0.66 LMNA (0.64) LMNAMAPTHTTKMT2ANPSR1
SCHEMBL3950037 0.66 CAMK2D (0.65) GBA1MAPTHTTMAPK1CAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 PAK4 2498/4885GBA1 2059/4885LMNA 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.